Newport Beach, CA – According to filings with the U.S. Securities and Exchange Commission, Aeon Biopharma is raising $25,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Marc Forth played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aeon Biopharma

AEON Biopharma is breaking new ground as the only company exclusively dedicated to the use of botulinum toxins for the treatment of debilitating medical conditions. Our therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payers and physicians. AEON Biopharma is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. We are dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market.

To learn more about Aeon Biopharma, visit http://www.aeonbiopharma.com/

Contact:
Marc Forth, President and Chief Executive Officer
949-260-1700
https://www.linkedin.com/in/mforth/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved